Ryo Miyata

8PUBLICATIONS
9CO-AUTHORS
Oncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 12, 2025
Postoperative Recurrence of ROS1-Rearranged Lung Adenocarcinoma: A Case Series.

Ryo Miyata, Ryota Sumitomo, Ryo Nakanobo

|Dec 04, 2025
Survival outcomes of alectinib in postoperative recurrent ALK-rearranged lung cancer.

Ryo Miyata, Masatsugu Hamaji, Hiroyuki Kurakami

|Dec 17, 2023
Effect of Tegafur-Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study.

Masaya Aoki, Ryo Miyata, Go Kamimura

|Aug 23, 2022
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study.

Ryo Miyata, Masatsugu Hamaji, Atsushi Kawaguchi

|Oct 15, 2021
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer.

Tetsuji Moriya, Masatsugu Hamaji, Akihiko Yoshizawa

Pageof 2